A Phase II Pilot Study of Anti‐PD‐L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation.
Saved in:
| Title: | A Phase II Pilot Study of Anti‐PD‐L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation. |
|---|---|
| Authors: | Fujii, Takeo1 (AUTHOR) takeo.fujii@nih.gov, Cimino‐Mathews, Ashley2 (AUTHOR), Lipkowitz, Stanley1 (AUTHOR), Lee, Min‐Jung3 (AUTHOR), Nair, Jayakumar1 (AUTHOR), Solarz, Britanny Brooke1 (AUTHOR), Zimmer, Alexandra1 (AUTHOR), Redd, Bernadette4 (AUTHOR), Levy, Elliot B.4 (AUTHOR), Rastogi, Shraddha3 (AUTHOR), Sato, Nahoko3 (AUTHOR), McCoy, Ann1 (AUTHOR), Steinberg, Seth M.5 (AUTHOR), Lee, Jung‐Min1 (AUTHOR) |
| Source: | Cancer Medicine. Dec2025, Vol. 14 Issue 23, p1-14. 14p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
